C
CalciMedica
Biotech & Life Sciences · San Diego, United States · Founded 2006 · IPO 2022
CalciMedica is engaged in the discovery and development of small molecule drugs for the treatment of acute and chronic inflammatory diseases and autoimmune disorders MoreLess
CalciMedica Inc. is a clinical-stage biotechnology company based in La Jolla, California. Founded in 2007 by Ken Stauderman and colleagues, the company focuses on developing treatments that target calcium release-activated calcium (CRAC) channels. These channels play a crucial role in various cellular functions, and by inhibiting them, CalciMedica aims to treat severe inflammatory diseases.
One of the company's flagship products is Auxora™, a drug designed to treat severe COVID-19 pneumonia. Interim results from clinical trials have shown promising outcomes when Auxora™ is used in combination with standard care. This positions CalciMedica as a key player in the fight against COVID-19 and potentially other inflammatory conditions.
CalciMedica primarily serves the healthcare sector, including hospitals, clinics, and research institutions. Their clients are typically healthcare providers looking for innovative treatments for severe inflammatory diseases. The company operates in the biotechnology market, which is known for its high growth potential but also significant risks due to the lengthy and costly process of drug development.
The business model of CalciMedica revolves around research and development (R&D) of novel therapeutic compounds. They invest heavily in clinical trials to prove the efficacy and safety of their drugs. Once a drug is proven effective, the company can either market it themselves or license it to larger pharmaceutical companies. Revenue is generated through the sale of these drugs, licensing agreements, and potentially milestone payments and royalties from partnerships.
In summary, CalciMedica is a biotechnology firm dedicated to developing innovative treatments for severe inflammatory diseases by targeting CRAC channels. Their focus on rigorous clinical trials and strategic partnerships helps them navigate the complex landscape of drug development and bring life-saving treatments to market.
Keywords: biotechnology, CRAC channels, Auxora™, COVID-19, inflammation, clinical trials, drug development, healthcare, pharmaceuticals, R&D.
Company overview
CalciMedica company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2006
- Headquarters
- San Diego, United States
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 76.7
Valuation & funding
CalciMedica funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT NON VCOther financing | Jun 2026 | $15M | — | Undisclosed | ↗ |
| POST IPO DEBTDebt | Mar 2025 | $10M | — | Avenue Capital Group | ↗ |
| POST IPO EQUITYOther financing | Jan 2024 | $20M | — | Aisling Capital · Deerfield · Soleus Capital · Stonepine Capital Management | ↗ |
| IPOOther financing | Jun 2023 | $0 | — | Undisclosed | — |
| ACQUISITIONOther financing | Nov 2022 | $0 | — | GrayBug | ↗ |
| SERIES DOther financing | Mar 2021 | Sanderling Ventures · GHS Fund · Valence Life Sciences · Quark Venture | — | ||
| SERIES COther financing | May 2020 | Mesa Verde Venture Partners · Valence Life Sciences · Sanderling Ventures | ↗ | ||
| EARLY VCOther financing | Apr 2014 | Undisclosed | — | ||
| DEBTDebt | Jul 2013 | Undisclosed | — | ||
| DEBTDebt | Nov 2012 | Undisclosed | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 18 |
| 2025 | 11 |
| 2024 | 11 |
| 2023 | 11 |
| 2022 | 11 |
| 2021 | 11 |
Growth signals
CalciMedica website traffic
Latest recorded traffic for CalciMedica is 4.7K monthly website visits, up 67.9% over the last three months. CalciMedica's team grew 63.6% over the past year.
Comparisons
CalciMedica compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 ID BiomedicalInfluenza vaccine research, development, and manufacturing |
Vancouver, Canada | Closed | — | $20M | $80M |
 Gyroscope TherapeuticsDeveloping one-time gene therapies for retinal diseases |
London, United Kingdom | Acquired | |||
 Stayble TherapeuticsNew treatment for chronic back pain |
Göteborgs Stad, Sweden | Operational | |||
 Cofactor GenomicsCofactor Genomics uses RNA to diagnose disease |
San Francisco, United States | Operational | |||
 Bio Green Med SolutionClinical-stage biopharma developing cell cycle cancer therapies |
Berkeley Heights, United States | Operational | |||
 Oxford ImmunotecProprietary T-cell based diagnostic tests for tuberculosis |
Milton, United Kingdom | Acquired | |||
 OxagenSmall molecule drugs for inflammatory and respiratory diseases |
Milton, United Kingdom | Operational | |||
 Janssen VaccinesVaccine development and manufacturing using proprietary platforms |
Leiden, Netherlands | Acquired |
Talent graph
CalciMedica's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where CalciMedica has talent and traffic
team presence
In the news
Latest news about CalciMedica
Recent press, funding announcements, and product moves mentioning CalciMedica — open to read from the original sources.
Market sentiment
What the market is saying about CalciMedica
An AI-synthesized read of the highest-engagement posts about CalciMedica on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CalciMedica’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.